Avoid common mistakes on your manuscript.
Dear Editor,
In BCR::ABL1-negative myeloproliferative neoplasms (MPN), mutation in the pseudokinase domain (JH2) of the non-receptor tyrosine Janus kinase 2 (JAK2) replacing phenylalanine for valine in exon 14 (JAK2V617F) is a major driver. JAK2V617F-mutation constitutively activates kinase function, thereby inducing cytokine receptor signaling [1]. In three percent of polycythemia vera patients JAK2 exon 12-mutation is present, and rare JAK2 exon 12-, exon 13-, and exon 14-mutations have been detected in other MPNs [2]. MPN may be associated with hypereosinophilia (HE) defined as a peripheral blood eosinophil count greater than 1.5/nL over a period of four weeks. HE is clonal or reactive in origin and may cause severe end-organ damage [3, 4]. We report a patient with a rare JAK2exon13InDel-mutation positive chronic eosinophilic leukemia (CEL), Löffler endocarditis, and bilateral cerebral infarctions.
A 50-year-old man presented to the emergency department with bilateral cerebral infarctions in the vascular area of the middle as well as the posterior cerebral artery and mainly in the watershed area (Fig. 1A–C). Leukocytosis of 69.2/nL with eosinophilia of 78% and no blasts were detected in the peripheral blood. Hemoglobin level was 8.2 mmol/L and platelet count 263/nL Abdominal ultrasound demonstrated extensive hepatosplenomegaly of 25 cm in the craniocaudal diameter. 1.5 years prior to admission, the patient had been diagnosed with prefibrotic phase of primary myelofibrosis (PMF) and associated eosinophilia. JAK2exon13InDel:p.Leu583_Ala586DelInsSer,c.1747_1756DelInsT- (JAK2exon13InDel) as well as DNMT3Ap.Phe732Ser,c.2195 T > C-mutation (DNMT3A) were detected. Since the patient was asymptomatic at the time of initial presentation, a watch and wait strategy had been pursued by his local hematologist. On admission, bone marrow biopsy demonstrated hypercellular bone marrow with eosinophilia of 52%, increased megakaryopoiesis without increase in blast count or myelofibrosis (Fig. 1D). PDGFRA-, PDGFRB-, FGFR1-, CALR-, and KITD816V-aberrations or the BCR::ABL1-rearrangement were excluded. The morphological findings in association with the JAK2exon13InDel-mutation were consistent with chronic eosinophilic leukemia. No chromosomal abnormalities were detected on bone marrow biopsy. Echocardiogram revealed extended endomyocardial fibrosis (Löffler endocarditis) circumventing two-thirds of the right ventricular atrium and thrombi in the left atrium as well as at the mitral valve (Fig. 1E). The electrocardiogram demonstrated new left bundle branch block, and troponin (high sensitive cTNI) was elevated up to 5236 pg/mL (normal range up to 34.2 pg/mL). Immediate coronary angiography excluded coronary artery disease or new thromboembolic event. On computed tomography scan, multiple pulmonary ground glass opacities were detected, consistent with interstitial pulmonary fibrosis related to eosinophilia (Fig. 1F). Because of leukocytosis with eosinophilia and multiple thromboembolic events, therapy with prednisone and cytarabine 100 mg/m2 per day over 3 days as well as therapeutic anticoagulation with intravenous unfractionated heparin was commenced. Due to increasing deterioration of vigilance and respiratory distress, intubation and mechanical ventilation were performed. Unfortunately, the patient developed several episodes of ventricular fibrillation. Despite intensive resuscitation efforts, the patient succumbed 6 days after admission.
In hypereosinophilia associated with subendocardial fibroses, infarctions in the watershed area due to eosinophilic endothelial changes independent of thromboembolism are common [5]. Moreover, thromboembolic complications are the leading cause of morbidity and mortality in MPN, and the presence of JAK2V617F-mutation as well as the allele burden have been shown to further increase this risk [6]. Promotion of cardiovascular disease has been described for JAK2-mutation by inflammation and neutrophil extracellular trap formation (NET) increasing cardiac dysfunction and thrombosis [7].
By the time of initial presentation of the JAK2exon13InDel-mutation positive CEL in our patient, this mutation had not been described in the literature. Patel et al. (2019) analyzed 4 patients with JAK2exon13InDel-mutations and eosinophilia, two of them with JAK2exon13InDel:p.Leu583_Ala586 DelInsSer,c.1747_1756DelInsT-mutation. This mutation contains a 4-amino-acid deletion (Leu583-Ala586Del) and an 1-amino-acid-insertion (InsSer) causing a conformational change by a rigid α-helix C within the JH2 domain of JAK2, and thus increased tyrosine kinase activity [8]. Recent research has demonstrated the correlation between clonal hematopoiesis of indeterminate potential (CHIP) and increased risk of cardiovascular events as well as ischemic stroke. Mutations in DNMT3A, TET2, ASXL1, and JAK2 are high-risk factors for coronary heart disease [9]. Dorsheimer et al. (2019) found a correlation between clonal size and clinical outcome in chronic heart failure for DNMT3A- and TET2-mutation dependent on variant allele frequency (VAF) [10]. The DNMT3A-mutation in our patient was detected by NGS at initial presentation with a VAF of 34% and at the time of admission to the emergency department with a VAF of 46%. Taking the involvement in cardiovascular function into account, the DNMT3A-mutation may have contributed to the cerebro- and cardiovascular complications in our patient. Patients with JAK2exon13InDel-mutation-associated MPN are at high risk for severe thromboembolic complications, and early initiation of treatment in these patients is essential.
References
Silvennoinen O, Ungureanu D, Niranjan Y et al (2013) New insights into the structure and function of the pseudokinase domain in JAK2. Biochem Soc Trans 41(4):1002–1007. https://doi.org/10.1042/BST20130005
Patel A, Juskevicius R, Mohan S (2023) Novel JAK2 exon 14 mutations L611S or N622Y in cis with JAK2 V617F are associated with distinct clinical phenotype of polycythemia vera and concurrent eosinophilia. Acta Haematol 146:76–81. https://doi.org/10.1159/000527695
Klag T, Schnetzke U, Benz R et al (2012) Lerich´s syndrome and Löffler endocarditis in a 30-year-old patient presenting with hypereosinophilic syndrome. Ann Hematol 91:139–141. https://doi.org/10.1007/s00277-011-1232-1
Khoury JD, Solary E, Abla O et al (2022) The 5th edition of the World Health Organization classification of haematolymphoid tumours: myeloid and histiocytic/dendritic neoplasms. Leukemia 36(7):1703–1719. https://doi.org/10.1038/s41375-022-01613-1
Ono R, Iwahana T, Kato H et al (2021) Literature reviews of stroke with hypereosinophilic syndrome. IJC Heart Vasc 37:100915. https://doi.org/10.1016/j.ijcha.2021.100915
Soudet S, Le Roy G, Cadet E et al (2022) JAK2 allele burden is correlated with a risk of venous but not arterial thrombosis. Thromb Res 211:1–5. https://doi.org/10.1016/j.thromres.2022.01.011
Wolach O, Sellar RS, Martinod K et al (2018) Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med 10(436): eaan8292. https://doi.org/10.1126/scitranslmed.aan8292
Patel AB, Franzini A, Leroy E et al (2019) JAK2ex13InDel drives oncogenic transformation and is associated with chronic eosinophilic leukemia and polycythemia vera. Blood 134(26):2388–2398. https://doi.org/10.1182/blood.2019001385
Stein A, Metzeler K, Kubasch AS et al (2022) Clonal hematopoiesis and cardiovascular disease: deciphering interconnections. Basic Res Cardiol 117(1):55. https://doi.org/10.1007/s00395-022-00969-w
Dorsheimer L, Assmus B, Rasper T et al (2019) Association of mutations contributing to clonal hematopoiesis with prognosis in chronic ischemic heart failure. JAMA Cardiol 25–33. https://doi.org/10.1001/jamacardio.2018.3965t
Funding
Open Access funding enabled and organized by Projekt DEAL. Karin G. Schrenk received travel support from Sobi, Gilead and Alexion (AstraZeneca). Andreas Hochhaus received research funding from Novartis, BMS, Pfizer and Incyte.
Author information
Authors and Affiliations
Contributions
Conceptualization: SE, AG, KGS. Figure design: SE and KGS. Molecular analysis: TH. Pathologic examination: HHK. Preparation of clinical data: SE, JZ, DB, SH, JH, AH, SO, PCS, FB, UT, AH, OWW, AG, and KGS. Writing original draft preparation: SE and KGS.
Approval of the final version: all authors.
Corresponding author
Ethics declarations
Ethical approval
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This article does not contain any studies with animals performed by any of the authors.
Informed consent
Informed consent was obtained from the sister of the patient.
Conflict of interest
The authors declare no competing interests.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
About this article
Cite this article
Eisenach, S., Zinke, J., Brämer, D. et al. Detection of a rare JAK2exon13InDel-mutation in chronic eosinophilic leukemia with bilateral cerebral infarctions and Löffler endocarditis. Ann Hematol 103, 363–365 (2024). https://doi.org/10.1007/s00277-023-05490-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00277-023-05490-1